Clinical Trials Browser

Gastro-enteropancreatic neuroendocrine tumor, Lymphoma, Rhabdomyosarcoma, Central Nervous System Neoplasms, Neuroectodermal Tumors, Primitive, Peripheral, Neuroendocrine Tumors

NCT05636618 2025-11-24

Targeted Alpha-Particle Therapy for Advanced Somatostatin Receptor Type 2 (SSTR2) Positive Neuroendocrine Tumors

Phase 1/2 Recruiting

260 enrolled

CNSEndocrineGastrointestinalNET

Gastro-enteropancreatic neuroendocrine tumor, Paraganglioma, Pheochromocytoma, Neuroendocrine Tumors

NCT06790706 2025-10-06

IMMUNORARE5

Phase 2 Recruiting

154 enrolled

EndocrineGastrointestinalGynecologicHead & NeckNETThoracic

Gastro-enteropancreatic neuroendocrine tumor, Carcinoid Tumor, Thymoma, Gestational Trophoblastic Disease, Thyroid Carcinoma, Anaplastic

NCT06256705 2025-09-22

OPERANDI-NET

Phase NA Recruiting

80 enrolled

EndocrineGastrointestinalNET

Gastro-enteropancreatic neuroendocrine tumor

NCT04609592 2025-09-09

Study of PRRT in Metastatic, World Health Organization (WHO) Grade 1 or 2, SSTR Positive, GEP-NET Who Are Candidates for Cytoreductive Surgery

Phase 1 Recruiting

10 enrolled

EndocrineGastrointestinalNET

Gastro-enteropancreatic neuroendocrine tumor

NCT05196087 2025-07-02

NIP IT!

Recruiting

500 enrolled

BreastDermatologicEndocrineGastrointestinalNET

Gastro-enteropancreatic neuroendocrine tumor, Breast Neoplasms, Melanoma, Neoplasm, Residual

NCT05997056 2024-07-16

Trial of Nab-sirolimus in Patients With Well-differentiated Neuroendocrine Tumors (NETs) of the Gastrointestinal Tract, Lung, or Pancreas Who Have Not Received Prior Treatment With mTOR Inhibitors

Phase 2 Recruiting

21 enrolled

EndocrineGastrointestinalNET

Gastro-enteropancreatic neuroendocrine tumor, Adenoma, Islet Cell, Neuroendocrine Tumors

NCT05701241 2024-06-14

SAUNA

Phase 4 Recruiting

270 enrolled

EndocrineGastrointestinalNET

Gastro-enteropancreatic neuroendocrine tumor, Neuroendocrine Tumors

NCT06402695 2024-05-07

ETNA-FPG

Recruiting

650 enrolled

EndocrineGastrointestinalNET

Gastro-enteropancreatic neuroendocrine tumor, Neuroendocrine Tumors

NCT05359146 2024-04-19

Beta plus

Phase EARLY_PHASE1 Recruiting

16 enrolled

EndocrineGastrointestinalNET

Gastro-enteropancreatic neuroendocrine tumor

NCT06155318 2023-12-20

68Ga-DOTATOC PET for the Evaluation of Gastroenteropancreatic Neuroendocrine Tumours

Recruiting

300 enrolled

EndocrineGastrointestinalNET

Gastro-enteropancreatic neuroendocrine tumor

NCT04949282 2022-12-23

SEPTRALU

Recruiting

5,000 enrolled

EndocrineGastrointestinalNET

Gastro-enteropancreatic neuroendocrine tumor, Digestive System Diseases, Digestive System Neoplasms, Endocrine System Diseases, Endocrine Gland Neoplasms, Gastrointestinal Diseases, Gastrointestinal Neoplasms, Intestinal Diseases, Intestinal Neoplasms, Neoplasms, Neoplasms by Histologic Type, Neoplasms by Site, Neoplasms, Germ Cell and Embryonal, Neoplasms, Nerve Tissue, Pancreatic Diseases, Pancreatic Neoplasms, Stomach Neoplasms, Neuroectodermal Tumors, Neuroendocrine Tumors

Clinical Trials

Multicenter Trial of ESK981 in Patients With Select Solid Tumors

NETTER-3

ACTION-1

FARINET

DENUTNE

KinLET

Targeted Alpha-Particle Therapy for Advanced Somatostatin Receptor Type 2 (SSTR2) Positive Neuroendocrine Tumors

IMMUNORARE5

OPERANDI-NET

Study of PRRT in Metastatic, World Health Organization (WHO) Grade 1 or 2, SSTR Positive, GEP-NET Who Are Candidates for Cytoreductive Surgery

NIP IT!

Trial of Nab-sirolimus in Patients With Well-differentiated Neuroendocrine Tumors (NETs) of the Gastrointestinal Tract, Lung, or Pancreas Who Have Not Received Prior Treatment With mTOR Inhibitors

SAUNA

ETNA-FPG

Beta plus

68Ga-DOTATOC PET for the Evaluation of Gastroenteropancreatic Neuroendocrine Tumours

SEPTRALU